| Inclusion Criteria: | 1) Pts must have histologically documented primary FIGO Stage III or IV or recurrent endometrial carcinoma whose potential for cure by radiation therapy or surgery alone or in combination is very poor. Pathologic documentation of the recurrence is required.
2) Patients must have measurable disease as defined in section 8, under Criteria for Response. Disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatment.
3) Patients may have received unlimited number of prior therapy, including platinum-based therapy, but such therapies must be discontinued at least 3 weeks prior to entry on this study. At least two weeks must have elapsed from the completion of radiotherapy and the start of therapy and six weeks must have elapsed if the radiotherapy involved the whole pelvis or over 50% of the spine, provided the acute effects of radiation treatment have resolved. Hormonal therapy may be discontinued at any time prior to initiating the protocol.
4) Patients must have adequate organ function as follows: Platelets >/= 100,000/ul; Granulocytes (ANC) >/= 1,500/ul; Creatinine </= 1.5 mg/dL SGPT (ALT) </= 3x upper limit of normal, and Bilirubin </= 1.5 times the institutional upper limit of normal. Neuropathy (sensory and motor) should be less than or equal to CTCAE grade 1.
5) Patients must have a Zubrod Performance Status of 0, 1, or 2.
6) Patients must have signed an approved informed consent.
7) Patients must have recovered from effects of recent surgery or radiotherapy. They should be free of significant infection. |